Naz Rahman
Stock Analyst at Maxim Group
(0.21)
# 4,372
Out of 5,182 analysts
38
Total ratings
15.15%
Success rate
-41.32%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $575 | $436.27 | +31.80% | 2 | Mar 18, 2026 | |
| NXGL NEXGEL | Maintains: Buy | $6 → $2 | $0.57 | +249.59% | 2 | Mar 12, 2026 | |
| SCNX Scienture Holdings | Initiates: Buy | $1.5 | $0.33 | +350.45% | 1 | Feb 24, 2026 | |
| KZIA Kazia Therapeutics | Maintains: Buy | $15 → $20 | $8.82 | +126.76% | 1 | Oct 2, 2025 | |
| AYTU Aytu BioPharma | Maintains: Buy | $9 → $7 | $2.55 | +174.51% | 2 | Sep 25, 2025 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $0.74 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $8.22 | +106.81% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $135 → $75 | $1.05 | +7,042.86% | 2 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $34.26 | +104.32% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $0.70 | - | 2 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $5.76 | - | 4 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $8 | $1.82 | +339.56% | 7 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.65 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $18.02 | +149.72% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $5.90 | +2,272.88% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.77 | - | 3 | Nov 17, 2023 |
Vertex Pharmaceuticals
Mar 18, 2026
Upgrades: Buy
Price Target: $575
Current: $436.27
Upside: +31.80%
NEXGEL
Mar 12, 2026
Maintains: Buy
Price Target: $6 → $2
Current: $0.57
Upside: +249.59%
Scienture Holdings
Feb 24, 2026
Initiates: Buy
Price Target: $1.5
Current: $0.33
Upside: +350.45%
Kazia Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $8.82
Upside: +126.76%
Aytu BioPharma
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $2.55
Upside: +174.51%
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.74
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $8.22
Upside: +106.81%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $135 → $75
Current: $1.05
Upside: +7,042.86%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $34.26
Upside: +104.32%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.70
Upside: -
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $5.76
Upside: -
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $1.82
Upside: +339.56%
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.65
Upside: -
Jul 26, 2024
Initiates: Buy
Price Target: $45
Current: $18.02
Upside: +149.72%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $5.90
Upside: +2,272.88%
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.77
Upside: -